Our August 2026 acquisition of Kashiv BioSciences provided Amneal with in-house biologics capabilities spanning cell-line and clone development, protein characterization, process development, clinical execution, regulatory expertise and scaled biologics manufacturing in India and U.S.
Our expanded biosimilars pipeline now includes over 20 programs, with 12+ commercial products expected to launch by 2030.
Data in the chart below as of August 2026. All trademarks listed below are the property of their respective owners.
Launch Date / Anticipated Launch Date
Launch Date / Anticipated Launch Date
Biologic: Avastin®
Therapeutic Area: Oncology
Biologic: NEUPOGEN
Therapeutic Area: Oncology
Biologic: Neulasta®
Therapeutic Area: Neutropenia
Biologic: Prolia®
Therapeutic Area: Osteoporosis
Biologic: XGEVA®
Therapeutic Area: Bone cancer
Therapeutic Area - Immunology/Allergy
Referenced Brand - XOLAIR®
Dosage Form - PFS
Approval - Q3’26*
Launch - Undisclosed
Therapeutic Area - Osteoporosis/Bone Cancer
Referenced Brand - PROLIA® & XGEVA®
Dosage Form - Vial
Approval - Q4’25*
Launch - Undisclosed
Launch Date / Anticipated Launch Date
Biologic: ORENCIA®
Therapeutic Area: Immunology
Biologic: CIMZIA®
Therapeutic Area: Immunology
Biologic: NPLATE®
Therapeutic Area: Hematology
Biologic: KEYTRUDA®
Therapeutic Area: Oncology
Biologic: OPDIVO®
Therapeutic Area: Oncology
Biologic: TRULICITY®
Therapeutic Area: Diabetes
Launch Date / Anticipated Launch Date
Biologic: DUPIXENT®
Therapeutic Area: Respiratory
Biologic: SKYRIZI®
Therapeutic Area: Immunology
Biologic: TREMFYA®
Therapeutic Area: Immunology
Biologic: Undisclosed
Therapeutic Area: Rheumatology
Biologic: Undisclosed
Therapeutic Area: Hematology
Biologic: Undisclosed
Therapeutic Area: Rheumatology
Biologic: Undisclosed
Therapeutic Area: Metabolic
Corporate
India